


PHARMACEUTICAL 2021

Ovid Therapeutics Inc. Rank 350 of 409









Ovid Therapeutics Inc. Rank 350 of 409



The relative strengths and weaknesses of Ovid Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ovid Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Ovid Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 250% points.

The company's Economic Capital Ratio, given in the ranking table, is -519%, being 165% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	74,843
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,063
Liabilities, Non-Current	0
Other Assets	947
Other Compr. Net Income	-2.5
Other Expenses	0
Other Liabilities	10,231
Other Net Income	395
Property and Equipment	136
Research and Development	63,417
Revenues	12,617
Selling, General and Administrative Expense	30,631

Output Variable	Value in 1000 USD
Assets	75,926
Liabilities	32,294
Expenses	94,048
Stockholders Equity	43,632
Net Income	-81,036
Comprehensive Net Income	-81,037
Economic Capital Ratio	-519%

